AstraZeneca gets CDSCO Panel Nod To update Prescribing Information of Antidiabetic FDC
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to AstraZeneca to update the prescribing information for the fixed-dose combination (FDC) antidiabetic drug Saxagliptin plus Dapagliflozin film-coated tablet with the modification under special warning and precautions for use as “If a patient presents with severe […]